Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers - ADME
Study identifier:D0520C00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Single-Centre, Phase I Study to Assess the Excretion, Metabolism and Plasma Pharmacokinetics following a Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
[C14]AZD9668
Sex
Male
Actual Enrollment
4
Study type
Interventional
Age
50 Years +
Date
Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jul 2010
Study design
Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 [C14]AZD9668 | Drug: [C14]AZD9668 Oral Solution 60 mg Single Dose |
Contacts
Investigators
Principal Investigator
Chris O'Brien
AstraZeneca R&D, Wilmington
